

### AI OPPORTUNITIES

- Span across multiple areas
- Admin/ student/ faculty/ operations/ legal
- Multimodal Al


### AI OPPORTUNITIES

- Generative AI- LLMs, Chat-GPT
- Image based


### **IMAGE BASED**

- Identify abnormalities
- Classify abnormalities
- Predict outcomes
- Coordinate care


## SO, WHAT DOES IT LOOK LIKE AIDOC?




# SO, WHAT DOES IT LOOK LIKE - AIDOC?




# SO, WHAT DOES IT LOOK LIKE - RAPIDAL CTP?




### AI WORKLIST INTEGRATION



間 76年 Osar ヘロ (1 8277M 単




### AI TOOLS IN RADIOLOGY- - LESION DETECTION



# **DETECTION**




DOB: 03-Feb-1950



#### qXR Interpretation

Lungs	
Opacity	YES:
Consolidation	
Fibrosis	NO.
Nodule	NO.
Other Quacities	YES
(Suspicion of Atelectasis)	
Emphysema	YES"
Cavity	NO-
Pieura	-
Blunted Costophrenic Angle	NO:
Pleural Effusion	NO-
Prieumothorax	YES
Mediastinum	
Tracheal Shift	NO-
Hilar Prominence	NO.
Mediastinal Widening	
Неал	
Cardiomegaly	
Diaphragm	120 mm
Raised/Tented Diaphragm	120,00
Pneumoperitoneum	
Bones	
Rib Fracture	

### NORMAL VS ABNORMAL



An Al tool can accurately identify normal and abnormal chest X-rays in a clinical setting, according to a study published in Radiology. The tool may greatly alleviate the heavy workload experienced by radiologists globally.

Mar 7, 2023

R https://www.rsna.org , news , march

Al Accurately Identifies Normal and Abnormal Chest X-Rays | RSNA



### AI TOOLS- CARE COORDINATION







### AI TOOLS- CARE COORDINATION

RAD AI CONTINUITY

# Improve patient care and reduce liability with automated follow-ups

Only 1 in 10 patients receive appropriate follow-up care. Rad Al Continuity closes the loop on follow-up recommendations for significant incidental findings in radiology reports.



### CHAT-GPT BASED USE BY RESIDENTS IN RADIOLOGY



#### You

give differential diagnosis for the following- a 2cm enhancing lesion in segment 5 that washes out on delayed phase, underlying cirrhosis



#### ChatGPT

When considering a 2cm enhancing lesion in segment 5 of the liver that washes out on delayed phase imaging, along with underlying cirrhosis, several differential diagnoses should be considered. The differential diagnosis for this presentation may include:

- Hepatocellular carcinoma (HCC): This is the most common primary malignant tumor of the liver, especially in the setting of cirrhosis. It typically presents as a hypervascular lesion with arterial phase enhancement that washes out on delayed phases.
- Dysplastic nodules: These are premalignant lesions commonly found in cirrhotic livers and can mimic HCC on imaging. They may also exhibit arterial phase enhancement and washout on delayed phases.
- 3. **Regenerative nodules**: These are benign nodules that can occur in cirrhotic livers. They may enhance during the arterial phase but usually do not exhibit washout on delayed phases.
- 4. Focal nodular hyperplasia (FNH): Though scommon in cirrhotic livers, FNH can present as a

### CHAT-GPT FOR DEVELOPING CONTENT

#### ChatGPT 3.5 V



develop CME content on TACE



#### ChatGPT

Title: Comprehensive Understanding of Transarterial Chemoembolization (TACE)

#### Introduction:

Transarterial Chemoembolization (TACE) is a cornerstone procedure in the management of hepatocellular carcinoma (HCC). It combines local chemotherapy with arterial embolization, targeting the tumor directly while minimizing systemic side effects. This CME content aims to provide a comprehensive understanding of TACE, including its indications, technique, patient selection, complications, and recent advancements.

#### **Learning Objectives:**



1. Understand the rationale behind Transarterial Chemoembolization (TACE) in the management of

#### Module 1: Understanding TACE

- Definition and historical background of TACE.
- Pathophysiology and rationale behind TACE in HCC.
- Comparison of TACE with other treatment modalities for HCC.
- Overview of TACE as a bridge to liver transplantation or as a palliative treatment.

#### Module 2: Indications and Patient Selection

- Criteria for patient selection: tumor size, number, and location; liver function; performance status;
   Child-Pugh classification.
- Multidisciplinary approach in patient selection: involving hepatologists, oncologists, interventional radiologists, and surgeons.
- Imaging modalities (CT, MRI, angiography) in assessing suitability for TACE.

#### Module 3: Technique of TACE

- Pre-procedural preparation: patient evaluation, laboratory investigations, and consent.
- \* Chemotherapeutic agents commonly used in TACE: doxorubicin, cisplatin, mitomycin-C, and

TACE

derstanding of Transarterial Chemoembolization (TACE)

olization (TACE) is a cornerstone procedure in the management of a (HCC). It combines local chemotherapy with arterial embolization, thy while minimizing systemic side effects. This CME content aims to a understanding of TACE, including its indications, technique, patient and recent advancements.

e behind Transarterial Chemoembolization (TACE) in the management of

### PREPARING LECTURE NOTES



#### You

prepare lecture notes for Y90 embolization

outcomes of Y 90 embolization for liver cancer



#### ChatGPT

Title: Outcomes of Y90 Embolization for Liver Cancer

- I. Introduction
- A. Overview of Liver Cancer
- B. Introduction to Yttrium-90 (Y90) Embolization
- C. Importance of Assessing Outcomes
- II. Procedure of Y90 Embolization
- A. Patient Selection Criteria
- B. Pre-procedural Preparation
- C. Technique and Administration of Y90
- D. Post-procedural Care and Follow-up





### DEVELOPING CASE SCENARIO



#### **ChatGPT**

Case Scenario:

#### Patient Profile:

Name: Sarah

Age: 32

Gender: Female

Occupation: Marketing Manager

Medical History: Diagnosed with relapsing-remitting multiple sclerosis (RRMS) two years ago.

#### Presenting Complaint:

Sarah presents to the neurology clinic with complaints of increased fatigue, weakness in her right leg, and difficulty with coordination over the past two weeks. She reports experiencing intermittent tingling sensations in both arm and legs, as well as occasional blurred vision in her right eye. Sarah mentions that her symptoms seem to worsen when she's stressed or fatigued.



Patient Profile:

- Name: Sarah
- Age: 32
- Gender: Female
- Occupation: Marl
- Medical History:

Presenting Compl Sarah presents to leg, and difficulty intermittent tingli right eye. Sarah m History of Present Illness:

Sarah reports that her initial symptoms of MS started four years ago when she noticed numbness and tingling in her left hand. At that time, she underwent a series of neurological examinations and diagnostic tests, including MRI scans, which revealed multiple lesions in her brain and spinal cord consistent with MS. She was subsequently diagnosed with relapsing-remitting multiple sclerosis (RRMS) and started on disease-modifying therapy (DMT).

Sarah states that she has been compliant with her DMT and has not experienced any significant relapses since starting treatment. However, she admits to occasional non-compliance with her prescribed exercise regimen and dietary recommendations due to work-related stress.

Physical Examination:

- Neurological examination reveals decreased strength (4/5) in the right leg compared to the left leg.
- Positive Romberg sign with mild swaying when standing with eyes closed.
- Intact sensation to light touch but diminished proprioception in the right leg.
- Visual acuity is 20/20 in the left eye and 2 in the right eye with evidence of a relative afferent pupillary defect (RAPD) on the right.





Patient Profile

- Name: Sarah
- Age: 32
- Gender: Fema
- Occupation:
- Medical Histo

Presenting Co Sarah present: leg, and difficu intermittent tir right eye. Sara

- MRI of the brain and spinal cord to assess for new lesions or evidence of disease progression.
- Lumbar puncture (CSF analysis) to evaluate for oligoclonal bands and evidence of inflammation in the central nervous system.
- Visual evoked potentials (VEP) to assess for optic nerve involvement.
- 'Blood tests to rule out other causes of neurological symptoms, including vitamin deficiencies and infectious diseases.

Assessment and Plan:

Based on Sarah's clinical presentation and diagnostic workup, the diagnosis of an MS relapse is suspected. The plan includes:

- 1. High-dose corticosteroid therapy (e.g., IV methylprednisolone) to reduce inflammation and shorten the duration of the relapse.
- 2. Symptomatic treatment for fatigue and neuropathic pain as needed.
- 3. Referral to physical therapy for gait training and strengthening exercises.
- 4. Close monitoring of symptoms and neurological status for signs of improvement or progression.
- 5. Counseling on the importance of stress management, regular exercise, and adherence to medication to optimize disease control ar  $\downarrow$  event future relapses.



### PREPARING ASSESSMENT QUESTIONS



#### You

prepare assesment questions for TARE over TACE



#### ChatGPT

Assessment questions comparing transarterial radioembolization (TARE) to transarterial chemoembolization (TACE) can help evaluate the understanding of key differences, indications, and outcomes between these two locoregional treatments for liver tumors. Here are some assessment questions:

#### Indications and Patient Selection:

- What are the primary indications for transarterial chemoembolization (TACE) in the treatment of liver tumors?
- What are the primary indications for transarterial radioembolization (TARE) in the treatment of liver tumors?
- How does patient selection differ between TACE and TARE? What factors influence the choice between these treatments?

#### 2. Mechanism of Action:

Describe the mechanism of action of treatment

between these treatments

#### You prepare ass

# O ChatGPT Assessmer chemoemb and outcom

#### 1. Indication

- What are of liver to the control of th
- What ar
- How do

#### Mechanis

Desc

#### 2. Mechanism of Action:

- Describe the mechanism of action of transarterial chemoembolization (TACE) in the treatment of liver tumors.
- Explain the mechanism of action of transarterial radioembolization (TARE) in the treatment of liver tumors. How does it differ from TACE?

#### 3. Efficacy and Survival Outcomes:

- Compare the efficacy of TACE and TARE in terms of tumor response rates and overall survival outcomes for hepatocellular carcinoma (HCC).
- In which patient populations has TARE shown potential superiority in survival outcomes compared to TACE? Provide examples from the literature.

#### 4. Safety and Adverse Events:

- Discuss the safety profile of transarterial chemoembolization (TACE), including common adverse events and complications.
- What are the main differences in the safety profile between transarterial radioembolization (TARE) and TACE? How do they compare in terms of post-embolization syndrome and other adverse events?

#### 5. Recurrence and Long-Term Outcomes:


Describe the recurrence rates following transarterial chemoembolization (TACE) for liver

# ADVANCED FEATURES (PAID)

draw the arterial anatomy of liver





#### DALL-E





#### **DALL-E**






Here are the images illustrating the cross section of the human midbrain with an emphasis on the

i i jonal view of the midbrain's in

You draw an image of a young woman palying violin against cherry blossom trees

#### DALL-E





### RESEARCH APPLICATIONS- PEER REVIEWED RESULTS

#### Consensus v




#### Consensus

Talked to chat.consensus.app

The factors that predict poor response post liver tumor embolization, such as Transarterial Chemoembolization (TACE) or Yttrium-90 (90Y) radioembolization, are crucial for tailoring patient treatment plans and managing expectations. Based on evidence from recent studies, several key factors have been identified:

- Alpha-fetoprotein (AFP) Levels: Lower AFP levels (<100 ng/mL) before embolization are associated with a better pathologic complete response (pCR), indicating a favorable prognosis post-embolization for hepatocellular carcinoma (HCC) patients (Yang et al., 2019).
- Tumor Characteristics: Single tumors and smaller tumor sizes (main tumor size ≤ 5 cm) are predictors of a better response to embolization. Larger tumors and the presence of microvascular tumor embolism are associated with a higher risk of recurrence and poorer outcomes (Joh et al., 2005), (Yuan et al., 2005).

### DATA ANALYSIS FROM SPREADSHEETS



#### Data Analyst

I see you've uploaded a file named "pt CT dose report 15 scan 1-24 to 3-24 total dose.xlsx". How can I assist you with it?

#### SO You

how does dose report compare to standard

0

#### Data Analyst

To compare the dose report from your file to standard values, I'll first need to understand the data in your file. This involves checking the type of dose metrics provided (like CTDIvol, DLP, etc.), the values for each patient or scan, and then comparing those values to established standard dose levels for similar types of CT scans.



Let's start by examining the content of your nie to identify the dose metrics and values it contains.

#### Data Analyst ~

equipment used, and patient demographics (like adult vs. pediatric patients). For adult head CT scans, a typical reference level for CTDIvol might be around 60 mGy, but this can vary.

Shall I proceed with summarizing the CTDIvol values for each anatomical area mentioned in the file? [>-]



#### Data Analyst

The cleaned data contains columns for the date, scan area, and CTDIvol values for up to three different anatomical areas per scan session. For simplicity, let's focus on summarizing the CTDIvol values for each mentioned anatomical area (e.g., Head, Face/Mandible, C-spine). We'll calculate the average CTDIvol for each area and then compare these averages to typical reference levels.

To proceed, I'll aggregate the CTDIvol values by the anatomical area and calculate the average dose. Let's start with this analysis. [>-]

The summary of CTDIvol values by anatom, area is as follows:

- **Head**: Average CTDIvol is approximately 46.59 mGy, with data from 14 scans.
- Face/Mandible: Average CTDIvol is approximately 29.52 mGy, with data from 9 scans.
- C-spine: Average CTDIvol is approximately 19.74 mGy, with data from 11 scans.

To compare these values to standard dose levels:

- For **Head CT scans**, a typical reference level might be around 60 mGy, suggesting that the average dose for head scans in this report is lower than the standard reference.
- For **Facial or Mandible CT scans**, specific reference levels can vary, but doses are generally expected to be lower than for full head scans due to the smaller volume of tissue being irradiated. The reported average seems to be within a reasonable range, though specific standards may vary.
- For C-spine (Cervical Spine) CT scans, reference levels are also lower than those for head scans due to the smaller and more focused scan area. The average dose reported here appears to be within a reasonable range.

It's important to note that reference levels can vary by region, institution, and the specific protocols used. These comparisons are may vith general benchmarks in mind. For more accurate assessments, it's best to consult the specific dose limits or reference levels provided by





# THANK YOU!

